ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
27 févr. 2023 09h20 HE
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which...